149 related articles for article (PubMed ID: 23187893)
1. Effect of duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) on hepatoblastoma cell lines.
Eicher C; Dewerth A; Ellerkamp V; Fuchs J; Schott S; Armeanu-Ebinger S
Pediatr Surg Int; 2013 Feb; 29(2):121-7. PubMed ID: 23187893
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluor-2'-deoxyuridine against human melanoma cells.
Schott S; Niessner H; Sinnberg T; Venturelli S; Berger A; Ikenberg K; Villanueva J; Meier F; Garbe C; Busch C
Int J Cancer; 2012 Nov; 131(9):2165-74. PubMed ID: 22323315
[TBL] [Abstract][Full Text] [Related]
3. ATP chemosensitivity testing of new antitumor duplex drugs linking 3`-C-ethynylycytidine (ECyd) and 2´-deoxy-5-fluorouridine (5-FdU) in comparison to standard cytostatica and combinations thereof.
Schott S; Wallwiener M; Kootz B; Seeger H; Fehm T; Neubauer H
Invest New Drugs; 2011 Jun; 29(3):506-13. PubMed ID: 19997962
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
Schott H; Schott S; Schwendener RA
Bioorg Med Chem; 2009 Oct; 17(19):6824-31. PubMed ID: 19744858
[TBL] [Abstract][Full Text] [Related]
5. Cytostatic activity of the duplex drug linking 2'-deoxy-5-fluorouridine (5FdU) with 3'-C-ethynylcytidine (ECyd) against gastric adenocarcinoma cell lines.
Weinreich J; Schott S; Königsrainer I; Zieker D; Königsrainer A; Schott H
Invest New Drugs; 2011 Dec; 29(6):1294-302. PubMed ID: 20596746
[TBL] [Abstract][Full Text] [Related]
6. Induction of apoptosis in cervical cancer cells by the duplex drug 5-FdU-ECyd, coupling 2'-deoxy-5-fluorouridine and 3'-C-ethinylcytidine.
Schott S; Brüning A
Gynecol Oncol; 2014 Nov; 135(2):342-8. PubMed ID: 25178996
[TBL] [Abstract][Full Text] [Related]
7. The conjugated antimetabolite 5-FdU-ECyd and its cellular and molecular effects on platinum-sensitive vs. -resistant ovarian cancer cells
Schott S; Wimberger P; Klink B; Grützmann K; Puppe J; Wauer US; Klotz DM; Schröck E; Kuhlmann JD
Oncotarget; 2017 Sep; 8(44):76935-76948. PubMed ID: 29100359
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxicity and antileukaemic activity of new duplexes linking 3-C-ethynylcytidine and 5-fluorodeoxyuridine.
Novotny L; Rauko P; Schott H
Anticancer Res; 2010 Dec; 30(12):4891-8. PubMed ID: 21187467
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of gastric adenocarcinoma and normal cell lines against combined or conjugated antimetabolites.
Weinreich J; Struller F; Küper M; Hack A; Königsrainer A; Schott TC
Anticancer Drugs; 2013 Apr; 24(4):375-83. PubMed ID: 23358120
[TBL] [Abstract][Full Text] [Related]
10. The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma.
Lieber J; Eicher C; Wenz J; Kirchner B; Warmann SW; Fuchs J; Armeanu-Ebinger S
BMC Cancer; 2011 Aug; 11():362. PubMed ID: 21854558
[TBL] [Abstract][Full Text] [Related]
11. Chemosensitivity of various peritoneal cancer cell lines to HIPEC and PIPAC: comparison of an experimental duplex drug to standard drug regimens in vitro.
Weinreich J; Struller F; Sautkin I; Giuashvili S; Reymond M; Königsrainer A; Schott TC
Invest New Drugs; 2019 Jun; 37(3):415-423. PubMed ID: 30019100
[TBL] [Abstract][Full Text] [Related]
12. Development of a drug resistance model for hepatoblastoma.
Eicher C; Dewerth A; Kirchner B; Warmann SW; Fuchs J; Armeanu-Ebinger S
Int J Oncol; 2011 Feb; 38(2):447-54. PubMed ID: 21132272
[TBL] [Abstract][Full Text] [Related]
13. The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cytotoxic drug and a p53-independent inducer of apoptosis in the androgen-independent human prostate cancer cell lines PC-3 and DU-145.
Cattaneo-Pangrazzi RM; Schott H; Schwendener RA
Prostate; 2000 Sep; 45(1):8-18. PubMed ID: 10960838
[TBL] [Abstract][Full Text] [Related]
14. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
[TBL] [Abstract][Full Text] [Related]
16. Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737.
Lieber J; Dewerth A; Wenz J; Kirchner B; Eicher C; Warmann SW; Fuchs J; Armeanu-Ebinger S
Oncol Rep; 2013 Feb; 29(2):646-52. PubMed ID: 23229825
[TBL] [Abstract][Full Text] [Related]
17. Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts.
Eicher C; Dewerth A; Thomale J; Ellerkamp V; Hildenbrand S; Warmann SW; Fuchs J; Armeanu-Ebinger S
Br J Cancer; 2013 Feb; 108(2):334-41. PubMed ID: 23257893
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and anticancer activities of amphiphilic 5-fluoro-2'-deoxyuridylic acid prodrugs.
Ludwig PS; Schwendener RA; Schott H
Eur J Med Chem; 2005 May; 40(5):494-504. PubMed ID: 15893023
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological inhibition of beta-catenin in hepatoblastoma cells.
Ellerkamp V; Lieber J; Nagel C; Wenz J; Warmann SW; Fuchs J; Armeanu-Ebinger S
Pediatr Surg Int; 2013 Feb; 29(2):141-9. PubMed ID: 23266718
[TBL] [Abstract][Full Text] [Related]
20. In vitro photodynamic therapy in pediatric epithelial liver tumors promoted by hypericin.
Seitz G; Krause R; Fuchs J; Heitmann H; Armeanu S; Ruck P; Warmann SW
Oncol Rep; 2008 Nov; 20(5):1277-82. PubMed ID: 18949433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]